Form 4: Teva CEO Francis Sells Shares After RSU Vesting

Teva Pharmaceutical Industries CEO Richard D. Francis executed a Rule 10b5-1 plan, acquiring shares from vested restricted share units and subsequently selling a portion to cover tax obligations.

Summary

• Richard D. Francis, President and CEO of Teva Pharmaceutical Industries Ltd., reported transactions on March 3, 2026.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on November 14, 2025.
• Francis acquired a total of 958,546 Ordinary Shares (67,231 and 891,315) through the vesting and exercise of Restricted Share Units (RSUs).
• He disposed of a total of 442,935 Ordinary Shares (30,903 and 412,032) to cover tax withholding obligations related to the RSU vesting.
• The shares sold for tax purposes had a weighted average price of $32.3599, with individual sales ranging from $31.72 to $32.865.
• Following these transactions, Francis beneficially owns 1,121,382 Ordinary Shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing routine executive compensation management and tax planning rather than a significant positive or negative signal about the company's immediate prospects.

Positives

• Vesting of Restricted Share Units (RSUs) indicates the satisfaction of performance criteria and/or time-based vesting conditions for the CEO.
• The transactions were pre-planned under a Rule 10b5-1 trading plan, demonstrating a structured approach to managing equity compensation and reducing concerns about opportunistic selling.

Negatives

• The sale of 442,935 Ordinary Shares, even for tax purposes, represents a reduction in the CEO's direct beneficial ownership of the company's stock.

Future Outlook

The filing indicates that 67,231 Restricted Share Units are scheduled to vest on March 3, 2027.

Management Comments

• The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.
• Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units.
• Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving the vesting of equity awards and subsequent sales to cover tax obligations, are a common and routine occurrence for executives in publicly traded companies across various industries. The use of a Rule 10b5-1 plan further indicates a pre-arranged, compliant approach to managing such compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting, but offset by the executive's continued beneficial ownership. The sale for tax purposes is a routine event and generally not considered a significant negative signal.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• 67,231 Restricted Share Units are scheduled to vest on March 3, 2027.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer, or any security holder.

Key Dates

Keywords

Teva Pharmaceutical Industries, TEVA, Richard D. Francis, Form 4, Insider Trading, Restricted Share Units, RSU, Stock Vesting, 10b5-1 Plan, Tax Withholding, Ordinary Shares, CEO